Aprea Therapeutics, Inc. Common stock Stock Prediction
AI-powered sentiment analysis and prediction trends for APRE, updated each market day.
APRE AI Sentiment
AI predicts Aprea Therapeutics, Inc. Common stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Aprea Therapeutics, Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Sector
Exchange
Market Cap
$8,406,099
Cap Tier
Employees
8
Headquarters
DOYLESTOWN, PA
Listed Since
Oct. 3, 2019
Website
APRE Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
APRE Volatility
Aprea Therapeutics, Inc. Common stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
